<DOC>
	<DOCNO>NCT00133328</DOCNO>
	<brief_summary>The JIKEI HEART Study design investigate whether concomitant treatment valsartan , angiotensin II receptor blocker ( ARB ) , addition conventional treatment , improve prognosis 3000 Japanese patient cardiovascular disease .</brief_summary>
	<brief_title>A Morbidity-Mortality Remodeling Study With Valsartan</brief_title>
	<detailed_description>Several recent clinical trial demonstrate angiotensin II receptor blocker ( ARBs ) cardiovascular well renal protective effect . However , problem number Asian patient little trial . The researcher examine treatment meaning ARB prognosis patient amalgamate either among high blood pressure , ischemic heart disease , congestive heart failure .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Clinical diagnosis hypertension , ischemic heart disease congestive heart failure Pregnancy Severe renal damage Severe liver damage Acute myocardial infarction</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>stroke</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>angina</keyword>
	<keyword>renal damage</keyword>
</DOC>